{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:01:34Z","timestamp":1740182494993,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtocrr.2024.100756","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T17:04:08Z","timestamp":1729789448000},"page":"100756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1\u2013Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study"],"prefix":"10.1016","volume":"6","author":[{"given":"Prashasti","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Offin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6109-5790","authenticated-orcid":false,"given":"Marjorie G.","family":"Zauderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2024.100756_bib1","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.22.02542","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"41","author":"Vogelzang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2024.100756_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial","volume":"48","author":"Fennell","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jtocrr.2024.100756_bib4","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2024.100756_bib6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2403817","article-title":"Wilms\u2019 tumour gene 1 (WT1) in human neoplasia","volume":"19","author":"Keilholz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtocrr.2024.100756_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1349-7006.1999.tb00733.x","article-title":"Expression of the Wilms\u2019 tumor gene WT1 in solid tumors and its involvement in tumor cell growth","volume":"90","author":"Oji","year":"1999","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF02982573","article-title":"The role of WT1 in oncogenesis: tumor suppressor or oncogene?","volume":"76","author":"Loeb","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib9","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib10","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2024.100756_bib11","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A\u00a0randomized Phase II trial of adjuvant Galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood-2017-09-805358","article-title":"Targeting WT1 in hematologic malignancies?","volume":"130","author":"Koehne","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtocrr.2024.100756_bib13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajh.24014","article-title":"WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides","volume":"90","author":"Brayer","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtocrr.2024.100756_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","article-title":"Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia","volume":"116","author":"Maslak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtocrr.2024.100756_bib16","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","article-title":"Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors","volume":"74","author":"Fu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib17","first-page":"201","article-title":"Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors","volume":"12","author":"Kleponis","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.jtocrr.2024.100756_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtocrr.2024.100756_bib20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2024.100756_bib21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtocrr.2024.100756_bib22","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib24","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404380","article-title":"Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein","volume":"20","author":"Pinilla-Ibarz","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtocrr.2024.100756_bib25","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.molimm.2010.06.005","article-title":"Structures of native and affinity-enhanced WT1 epitopes bound to HLA-a\u22170201: implications for WT1-based cancer therapeutics","volume":"47","author":"Borbulevych","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jtocrr.2024.100756_bib26","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.leukres.2006.02.010","article-title":"Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-a\u22170201 molecules","volume":"30","author":"Gomez-Nunez","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib27","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/cancers15051458","article-title":"Phase I study of a multivalent WT1 peptide vaccine (Galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission","volume":"15","author":"Manning-Geist","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2024.100756_bib28","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18693.1","article-title":"Strategies for developing and optimizing cancer vaccines","volume":"8","author":"Maeng","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.jtocrr.2024.100756_bib29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtocrr.2024.100756_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324001267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T02:29:57Z","timestamp":1737426597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364324001267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666364324001267"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100756","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1\u2013Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100756"}}